Decellularized Cell Aggregate Scaffolds Without Animal-Derived Tissue
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Decellularized tissues are difficult to manufacture and require animal-derived biological tissues, leading to challenges in graft compatibility and rejection.
Innovation Solution
A decellularized cell aggregate is produced by culturing cells to form a cell aggregate and then decellularizing it, ensuring specific pore diameters and lamin content, which can be made from immortalized cells or mixed cell types, using methods like high hydrostatic pressure treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If decellularized tissues are used to improve graft compatibility, then immune rejection is avoided, but manufacturing difficulty increases and animal-derived tissues are required
Solution Approach 1:
The patent creates a decellularized cell aggregate that copies the essential structural features of natural extracellular matrix without requiring animal tissues. By using cultured cells to form aggregates and then removing the cellular components, the invention produces a scaffold that mimics natural ECM architecture while being manufactured from human cells, thus resolving the contradiction between graft compatibility and manufacturing ease
Solution Approach 2:
The patent employs a disposable cell aggregate system where cells are cultured, decellularized, and then the resulting scaffold is used. The cell aggregate serves as a temporary vehicle that delivers the ECM structure to the target site, after which it is naturally degraded. This approach simplifies manufacturing compared to permanent animal tissue grafts while maintaining biocompatibility
2Reliability
If animal-derived biological tissues are used for decellularization, then graft compatibility is improved, but manufacturing complexity increases
Solution Approach 1:
The patent uses cultured cells to self-assemble into aggregates that naturally form ECM structures. The cells themselves create the matrix architecture through their natural behavior during culture, eliminating the need for complex external manufacturing processes. After decellularization, the self-organized ECM structure remains as the functional graft material
Solution Approach 2:
The patent changes the source material parameter from animal tissues to cultured human cells, and changes the structural organization parameter from disorganized tissue to controlled cell aggregates. This parameter transformation simplifies the manufacturing process while maintaining or improving biological compatibility through better control over ECM structure and composition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for easy manufacturing of decellularized grafts with enhanced cell viability and biocompatibility, serving as a scaffold for cell culture and transplantation.
Implementation Method 1
using methods like high hydrostatic pressure treatment
Data Source
Figure 1~3
Figure 3
Figure 4~5
AI summary
The object of the present invention is to provide a decellularized graft which is easily manufactured. The problem can be solved by a decellularized cell aggregate, wherein a cultured cell aggregate is decellularized, and surface pores with pore diameter of 5µm or more are 3 to 45 per 11088µm2 of aggregate surface, and/or a decellularized cell aggregate, wherein a cultured cell spheroid is decellularized, and lamin of 10pg/mg or more is contained with respect to the decellularized cell aggregate.